654 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors

• Marcus Butler,
• Daniel J Olson,
• Antonio Giordano,
• Ecaterina Dumbrava,
• Benjamin Schlechter,
• Maria Apostolopoulou,
• Mridula George,
• Brooke Pieke,
• Kara Moss,
• Deyaa Adib,
• Sam Saibil,
• Miriam Gavriliuc,
• Emily Lichtenstein,
• Jill Geisberger,
• D’Arcy Kirkwood,
• Salina Dang

Affiliations

Marcus Butler

4University Health Network Princess Margaret, Toronto, ON, Canada

Daniel J Olson

1University of Chicago, Chicago, IL, USA

Antonio Giordano

2The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Ecaterina Dumbrava

2The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Benjamin Schlechter

9Dana-Farber Cancer Institute, Boston, MA, USA

Maria Apostolopoulou

6Triumvira Immunologics Inc., Falmouth, MA, USA

Mridula George

3Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

Brooke Pieke

1University of Chicago, Chicago, IL, USA

Kara Moss

8Triumvira Immunologics, Austin, TX, USA

Deyaa Adib

8Triumvira Immunologics, Austin, TX, USA

Sam Saibil

3University Health Network Princess Margaret, Toronto, ON, Canada

Miriam Gavriliuc

2The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Emily Lichtenstein

3Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

Jill Geisberger

4University Health Network Princess Margaret, Toronto, ON, Canada

D’Arcy Kirkwood

7Triumvira Immunologics, Austin, TX, USA

Salina Dang

7Triumvira Immunologics, Austin, TX, USA